HRP20170734T1 - Povećana biodostupnost lijeka u terapiji naltreksonom - Google Patents
Povećana biodostupnost lijeka u terapiji naltreksonom Download PDFInfo
- Publication number
- HRP20170734T1 HRP20170734T1 HRP20170734TT HRP20170734T HRP20170734T1 HR P20170734 T1 HRP20170734 T1 HR P20170734T1 HR P20170734T T HRP20170734T T HR P20170734TT HR P20170734 T HRP20170734 T HR P20170734T HR P20170734 T1 HRP20170734 T1 HR P20170734T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- bupropion
- use according
- Prior art date
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title claims 17
- 229960003086 naltrexone Drugs 0.000 title claims 17
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 28
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 14
- 229960001058 bupropion Drugs 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- 235000012054 meals Nutrition 0.000 claims 8
- 235000013305 food Nutrition 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Farmaceutski pripravak za upotrebu za liječenje prekomjerne težine ili pretilosti koji sadrži formulaciju naltreksona s usporenim oslobađanjem ili njegove farmaceutski prihvatljive soli i formulaciju bupropiona s usporenim oslobađanjem ili njegove farmaceutski prihvatljive soli, naznačen time da se navedeni pripravak daje u kombinaciji s hranom.
2. Farmaceutski pripravak za upotrebu prema zahtjevu 1, naznačen time da je količina navedenog bupropiona ili njegove farmaceutski prihvatljive soli u opsegu od oko 90 mg do oko 360 mg dnevno, te je količina naltreksona ili njegove farmaceutski prihvatljive soli u opsegu od oko 4 mg do oko 32 mg dnevno.
3. Farmaceutski pripravka za upotrebu prema zahtjevu 1, naznačen time da navedeni naltrekson ili njegova farmaceutski prihvatljiva sol sadrži nesekvestriranu formulaciju naltreksona ili njegove farmaceutski prihvatljive soli.
4. Farmaceutski pripravka za upotrebu prema zahtjevu 1, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol, daje istovremeno s bupropionom ili njegovom farmaceutski prihvatljivom soli.
5. Farmaceutski pripravka za upotrebu prema zahtjevu 1, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol, daje prije ili poslije bupropiona ili njegove farmaceutski prihvatljive soli.
6. Farmaceutski pripravka za upotrebu prema zahtjevu 1, naznačen time da su navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i bupropion ili njegova farmaceutski prihvatljiva sol u jednom obliku doziranja.
7. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da navedena hrana sadrži obrok s visokim sadržajem masti.
8. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 7, naznačen time da navedena hrana sadrži obrok izabran iz skupine koju čine umjereno kaloričan obrok s umjerenim sadržajem masti od oko 575 kalorija, a mast iznosi oko 23% ukupnog kalorijskog sadržaja; visoko kalorijski obrok sa visokim sadržajem masti od oko 1000 kalorija, a mast čini oko 50% ukupnog kalorijskog sadržaja; i obrok koji pripada u okvir opsega definiranog navedenim umjereno kaloričnim obrokom s umjerenim sadržajem masti i navedenim visoko kaloričnim obrokom sa visokim sadržajem masti.
9. Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 8, naznačen time da je navedena hrana umjereno kaloričan obrok s umjerenim sadržajem masti.
10. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da raspored davanja navedenog naltreksona ili njegove farmaceutski prihvatljive soli i navedenog bupropiona ili njegove farmaceutski prihvatljive soli je:
oko 8 mg navedenog naltreksona ili njegove farmaceutski prihvatljive soli i oko 90 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku prvog tjedna tretmana;
oko 16 mg navedenog naltreksona ili njegove farmaceutski prihvatljive soli i oko 180 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku drugog tjedna tretmana;
oko 24 mg naltreksona ili njegove farmaceutski prihvatljive soli i oko 270 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku trećeg tjedna tretmana; i
oko 32 mg navedenog naltreksona ili njegove farmaceutski prihvatljive soli i oko 360 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku četvrtog tjedna tretmana i bilo kojeg slijedećeg tjedna tretmana.
11. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju kao dvije tablete od 8 mg naltreksona s usporenim oslobađanjem dva puta dnevno i dvije tablete od 90 mg bupropiona s usporenim oslobađanjem dva puta dnevno.
12. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju tijekom najmanje 28 tjedana.
13. Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju tijekom najmanje 56 tjedana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41939510P | 2010-12-03 | 2010-12-03 | |
| EP11845186.3A EP2646031B9 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
| PCT/US2011/063177 WO2012075459A1 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170734T1 true HRP20170734T1 (hr) | 2017-08-11 |
Family
ID=46172304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170734TT HRP20170734T1 (hr) | 2010-12-03 | 2017-05-16 | Povećana biodostupnost lijeka u terapiji naltreksonom |
| HRP20210618TT HRP20210618T1 (hr) | 2010-12-03 | 2021-04-19 | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210618TT HRP20210618T1 (hr) | 2010-12-03 | 2021-04-19 | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130245056A1 (hr) |
| EP (4) | EP2646031B9 (hr) |
| JP (5) | JP6008866B2 (hr) |
| KR (5) | KR102258043B1 (hr) |
| CN (1) | CN103313711A (hr) |
| AR (2) | AR093182A1 (hr) |
| AU (2) | AU2011336304B2 (hr) |
| BR (1) | BR112013013390A2 (hr) |
| CA (1) | CA2819262A1 (hr) |
| CL (1) | CL2013001564A1 (hr) |
| CY (2) | CY1118968T1 (hr) |
| DK (3) | DK2646031T3 (hr) |
| ES (2) | ES2625527T3 (hr) |
| FI (1) | FI3884947T3 (hr) |
| HR (2) | HRP20170734T1 (hr) |
| HU (2) | HUE053831T2 (hr) |
| IL (3) | IL226504B (hr) |
| LT (3) | LT3222280T (hr) |
| MX (1) | MX356801B (hr) |
| PL (3) | PL3884947T3 (hr) |
| PT (3) | PT3884947T (hr) |
| RS (3) | RS65198B1 (hr) |
| RU (1) | RU2640561C2 (hr) |
| SI (2) | SI2646031T1 (hr) |
| TW (1) | TWI618536B (hr) |
| WO (1) | WO2012075459A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| PT3884947T (pt) * | 2010-12-03 | 2024-02-16 | Nalpropion Pharmaceuticals Llc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
| PE20150358A1 (es) | 2012-06-06 | 2015-04-06 | Orexigen Therapeutics Inc | Metodos para el tratamiento del sobrepeso y de la obesidad |
| WO2016125109A1 (en) * | 2015-02-07 | 2016-08-11 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition for the treatment of obesity |
| AU2018244806B2 (en) * | 2017-03-28 | 2023-12-21 | LDN Pharma Limited | An agent that increases the expression of the Bcl2-associated agonist of cell death for the treatment of cancer |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| EP1772147A2 (en) * | 2003-03-17 | 2007-04-11 | Japan Tobacco, Inc. | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| EP1907005A1 (en) | 2005-07-27 | 2008-04-09 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20070179168A1 (en) | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| PT2484346T (pt) * | 2006-06-19 | 2017-04-26 | Alpharma Pharmaceuticals Llc | Composições farmacêuticas |
| KR101264789B1 (ko) | 2006-06-30 | 2013-05-15 | 엘지디스플레이 주식회사 | 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법 |
| WO2008011150A1 (en) * | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| ES2344440T3 (es) * | 2006-11-09 | 2010-08-26 | Orexigen Therapeutics, Inc. | Formulaciones farmaceuticas en capas que comprenden una capa intermedia de disolucion rapida. |
| KR20140088619A (ko) | 2006-11-09 | 2014-07-10 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| KR20100016445A (ko) * | 2007-04-11 | 2010-02-12 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| PT3884947T (pt) | 2010-12-03 | 2024-02-16 | Nalpropion Pharmaceuticals Llc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
-
2011
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active IP Right Grant
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active IP Right Grant
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 CA CA2819262A patent/CA2819262A1/en active Granted
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Application Filing
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Application Discontinuation
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active IP Right Grant
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 EP EP23209711.3A patent/EP4349369A3/en active Pending
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en active Application Filing
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
-
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
-
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
-
2017
- 2017-05-16 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
-
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
-
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
-
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
-
2021
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
-
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
-
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| HRP20210239T1 (hr) | Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina | |
| JP2013544290A5 (hr) | ||
| HRP20141008T1 (hr) | Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2009525343A5 (hr) | ||
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| JP2007238598A5 (hr) | ||
| JP2009525985A5 (hr) | ||
| MX2010002780A (es) | Formulacion de farmaco resistente al abuso. | |
| JP2018527305A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| JP2010527347A5 (hr) | ||
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| JP2013516493A5 (hr) | ||
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| JP2017525771A (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| EP3445358B1 (en) | Administration of dihydroberberine | |
| RS53087B (en) | SOLID PHARMACEUTICAL COMPOSITIONS OF PERMANENT COMPOSITION CONTAINING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THERAPY USE | |
| JP2011510922A5 (hr) | ||
| WO2011019735A3 (en) | Nutritional supplements | |
| WO2014006636A3 (en) | Stable compositions of fesoterodine | |
| JP2015501849A5 (hr) |